Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rituximab

- PMLiVE

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more

A rapid round up of pharma, biotech and healthcare news

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

Roche Basel Switzerland

Ocrevus helps Roche stave off biosimilar threat

Its low price strategy for the CD20-targeting antibody is paying off

- PMLiVE

Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more

A rapid round up of pharma, biotech and healthcare news

- PMLiVE

Sanofi appoints ex-Roche Reed as new R&D head

John Reed to take up post after leaving Roche last month

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

AbbVie’s upadacitinib aces phase III trial

Arthritis drug outperformed both placebo and Humira in the study

Biogen Idec building

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Agreement could see Europe access Imraldi as early as October this year

- PMLiVE

First blood to Roche in Hemlibra patent fight with Shire

The new haemophilia drug does not infringe Baxalta’s patent, rules Tokyo court

Roche Basel Switzerland

Another Tecentriq win for Roche as Avastin combo boosts survival

The Swiss pharma group reported a 38% improvement in PFS in NSCLC patients

- PMLiVE

AbbVie slumps on trial results for would-be blockbuster Rova-T

The pharma group saw its shares plummet after the news broke

- PMLiVE

New data could put Roche’s Tecentriq first in squamous lung cancer

NSCLC patients on the drug saw a reduced risk of disease progression

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links